AF9 Antikörper (N-Term)

Produktnummer ABIN358675

Dieses Kaninchen Polyklonal-Antikörper erkennt spezifisch AF9 in WB und EIA. Er zeigt eine Reaktivität gegenüber Human.

Kurzübersicht für AF9 Antikörper (N-Term) (ABIN358675)

Target: AF9 (MLLT3) (Protein AF-9 (MLLT3))

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser AF9 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), Enzyme Immunoassay (EIA)

Produktdetails anti-AF9 Antikörper

Bindungsspezifität: N-Term

Spezifität: This antibody recognizes Human MLLT3 (N-term).

Aufreinigung: Prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS

Immunogen: KLH conjugated synthetic peptide selected from the N-terminal region of Human MLLT3

Isotyp: Ig Fraction

Anwendungsinformationen

Applikationshinweise: ELISA: 1/1,000. Western blotting: 1/100 - 1/500.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 0.25 mg/mL

Buffer: PBS containing 0.09 % (W/V) Sodium Azide as preservative

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handhabung: Avoid repeated freezing and thawing.

Lagerung: 4 °C/-20 °C

Informationen zur Lagerung: Store undiluted at 2-8 °C for one month or (in aliquots) at-20 °C for longer.

Details zu AF9

Target: AF9 (MLLT3) (Protein AF-9 (MLLT3))

Andere Bezeichnung: MLLT3 / AF9

Hintergrund: The human AF9 gene is one of the most common fusion partner genes with the ALL1 gene at 11q23 (also called MLL), resulting in the t(9,11)(p22,q23). The AF9 gene is more than 100 kb, and 2 patient breakpoint cluster regions (BCRs) have been identified, BCR1 is within intron 4, previously called site A, whereas BCR2 or site B spans introns 7 and 8. Several different structural elements have been identified in AF9, including a colocalizing in vivo DNA topo II cleavage site and an in vitro DNase I hypersensitive (DNase 1 HS) site in intron 7 in BCR2. Reversibility experiments demonstrated a religation of the topo II cleavage sites. In addition, 2 scaffold associated regions (SARs) are located centromeric to the topo II and DNase I HS cleavage sites and border breakpoint regions in 2 leukemic cells lines: SAR1 is located in intron 4, whereas SAR2 encompasses parts of exons 5-7. The patient breakpoint regions of AF9 share the same structural elements as the MLL BCR. A DNA breakage and repair model for nonhomologous recombination between MLL and its partner genes, particularly AF9, has been proposed.Synonyms: ALL1 fused gene from chromosome 9 protein, Myeloid/lymphoid or mixed-lineage leukemia translocated to chromosome 3 protein, Protein AF-9, YEATS domain-containing protein 3, YEATS3

Gen-ID: 4300, 9606

UniProt: P42568